These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 20865027)

  • 1. Anticoagulant therapy: warfarin sensitivity genotyping closer to clinical practice.
    van der Zee SA; Halperin JL
    Nat Rev Cardiol; 2010 Oct; 7(10):549-50. PubMed ID: 20865027
    [No Abstract]   [Full Text] [Related]  

  • 2. The long and winding road to warfarin pharmacogenetic testing.
    Ginsburg GS; Voora D
    J Am Coll Cardiol; 2010 Jun; 55(25):2813-5. PubMed ID: 20579536
    [No Abstract]   [Full Text] [Related]  

  • 3. Dosing anticoagulant therapy with coumarin drugs: is genotyping clinically useful? No.
    Mannucci PM; Spreafico M; Peyvandi F
    J Thromb Haemost; 2008 Sep; 6(9):1450-2. PubMed ID: 18627441
    [No Abstract]   [Full Text] [Related]  

  • 4. Pathology consultation on warfarin pharmacogenetic testing.
    Stack G;
    Am J Clin Pathol; 2011 Jan; 135(1):13-9. PubMed ID: 21173120
    [No Abstract]   [Full Text] [Related]  

  • 5. [Polymorphisms of genes CYP2C9 and VKORC1 in patients with venous thromboembolic complications in Moscow population: effects on stability of anticoagulant therapy and frequency of hemorrhage].
    Vorob'eva NM; Panchenko EP; Dobrovol'skiĭ AB; Titaeva EV; Khasanova ZB; Konovalova NV; Postnov AIu; Kirienko AI
    Ter Arkh; 2011; 83(6):59-65. PubMed ID: 21786578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Refining the use of warfarin through genetic testing.
    Lee SC
    Int Angiol; 2008 Aug; 27(4):271-3. PubMed ID: 18677287
    [No Abstract]   [Full Text] [Related]  

  • 7. Using genetic testing to guide warfarin therapy.
    Ungerer LL; Pestka EL; Messner PK
    Nursing; 2012 May; 42(5):63-5. PubMed ID: 22531080
    [No Abstract]   [Full Text] [Related]  

  • 8. Genetic testing for warfarin dosing? Not yet ready for prime time.
    Bussey HI; Wittkowsky AK; Hylek EM; Walker MB
    Pharmacotherapy; 2008 Feb; 28(2):141-3. PubMed ID: 18225960
    [No Abstract]   [Full Text] [Related]  

  • 9. Dynamic pharmacogenetic models in anticoagulation therapy.
    Bon Homme M; Reynolds KK; Valdes R; Linder MW
    Clin Lab Med; 2008 Dec; 28(4):539-52. PubMed ID: 19059061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenomic testing for warfarin dosing: we are ready now.
    Wu AH
    Expert Rev Cardiovasc Ther; 2009 Dec; 7(12):1483-5. PubMed ID: 19954308
    [No Abstract]   [Full Text] [Related]  

  • 11. Warfarin and pharmacogenomic testing: what would Pascal do?
    Teagarden JR
    Pharmacotherapy; 2009 Mar; 29(3):245-7. PubMed ID: 19249943
    [No Abstract]   [Full Text] [Related]  

  • 12. Genetic help for a blood-thinner balancing act? There's little evidence yet that a genetic test improves the safety of warfarin.
    Harv Heart Lett; 2007 Dec; 18(4):1-2. PubMed ID: 18219801
    [No Abstract]   [Full Text] [Related]  

  • 13. Prediction of warfarin dose: why, when and how?
    Eriksson N; Wadelius M
    Pharmacogenomics; 2012 Mar; 13(4):429-40. PubMed ID: 22379999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study).
    Epstein RS; Moyer TP; Aubert RE; O Kane DJ; Xia F; Verbrugge RR; Gage BF; Teagarden JR
    J Am Coll Cardiol; 2010 Jun; 55(25):2804-12. PubMed ID: 20381283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The VKORC1 and CYP2C9 genotypes are associated with over-anticoagulation during initiation of warfarin therapy in children.
    Biss TT; Avery PJ; Williams MD; Brandão LR; Grainger JD; Kamali F
    J Thromb Haemost; 2013 Feb; 11(2):373-5. PubMed ID: 23279643
    [No Abstract]   [Full Text] [Related]  

  • 16. [Recurrent thromboses and hemorrhagic complications in patients with antiphospholipid syndrome during therapy with warfarin plus aspirin].
    Kondrat'eva LV; Patrusheva NL; Patrushev LI; Aleksandrova EN; Kovalenko TF; Ostriakova EV; Reshetniak TM
    Ter Arkh; 2010; 82(5):33-9. PubMed ID: 20597268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polymorphisms in VKORC1 have more impact than CYP2C9 polymorphisms on early warfarin International Normalized Ratio control and bleeding rates.
    Lund K; Gaffney D; Spooner R; Etherington AM; Tansey P; Tait RC
    Br J Haematol; 2012 Jul; 158(2):256-261. PubMed ID: 22571356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genotype and adverse drug reactions to warfarin.
    Byron KA; Dear AE
    Med J Aust; 2007 Jul; 187(1):61-2. PubMed ID: 17605718
    [No Abstract]   [Full Text] [Related]  

  • 19. Warfarin dose requirement for patients with both VKORC1 3673A/A and CYP2C9*3/*3 genotypes.
    Fukuda T; Tanabe T; Ohno M; Tougou K; Fujio Y; Azuma J; Yamamoto I; Takeda A
    Clin Pharmacol Ther; 2006 Nov; 80(5):553-4. PubMed ID: 17112813
    [No Abstract]   [Full Text] [Related]  

  • 20. An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients.
    Meckley LM; Wittkowsky AK; Rieder MJ; Rettie AE; Veenstra DL
    Thromb Haemost; 2008 Aug; 100(2):229-39. PubMed ID: 18690342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.